Novo Nordisk: A Stock Caught Between Eli Lilly’s Shadow and an AI-Led Renaissance

Novo Nordisk stock nears 47% annual loss after CagriSema trails Eli Lilly's Zepbound. Promising Zenagamtide pill and AI pivot offer long-term hope but pricing pressure persists.

Novo Nordisk’s shares are nursing a near-47% loss over the past year, and the latest clinical data did little to arrest the decline. At the American Diabetes Association conference in New Orleans, the Danish drugmaker unveiled a mixed bag: a promising new pill called Zenagamtide, but also a painful defeat for its much-anticipated CagriSema regime. In a head-to-head trial, CagriSema delivered a 23% weight reduction after 84 weeks — a respectable figure, yet one that trails Eli Lilly’s Zepbound at 25.5%. The market’s disappointment was palpable, and the stock, which closed at €36.58 above its 50-day moving average, still sits nearly 12% below the 200-day line. An annualised volatility of 34% underscores the jitters.

Yet the narrative is not one of unrelenting gloom. Zenagamtide, a phase 2 candidate tested on over 250 adults with type 2 diabetes, posted a 14.6% weight loss at the highest dose, with no plateau in sight. Novo Nordisk plans to launch a phase 3 programme in the second half of 2026, though results are unlikely before 2028. That timeline puts pressure on the company to keep investor faith alive in the interim. CEO Mike Doustdar used the conference to pivot the conversation towards longevity and aesthetic medicine, pointing to data that Semaglutide reduces the biological age of the heart and kidneys — effects that appear before significant weight loss occurs. Novo Nordisk now considers itself part of the longevity sector.

Parallel to the clinical story, the company is leaning into artificial intelligence. It has integrated OpenAI functions into research, production and supply chains, aiming for a broad rollout by the end of 2026. OpenAI’s June update explicitly mentions Novo Nordisk in connection with its GPT-Rosalind research model, designed to accelerate tasks such as proof generation, experimental design and data validation. While AI strengthens the long-term innovation pipeline, it does little to repair the immediate pricing pressure that has hammered the stock. The market’s core concern remains the erosion of selling prices in the US, compounded by generic competition and patent expirations for Semaglutide in some regions.

The share buyback programme, worth up to 15 billion Danish kroner and running until February 2027, has done little to buoy the stock. As of early June, Novo had repurchased nearly 5 billion kroner of its own shares, yet the equity languishes at roughly €35.83 — a level that implies a market capitalisation of around €163 billion. The 52-week high of €70 feels like a distant memory. The RSI, at 45.7, signals no overheating, and the stock has clawed back about 20% from its March trough, suggesting the worst of the selling may be behind it.

What the drugmaker needs now is not just a story, but proof. Higher volumes of GLP-1 drugs are helping, but they must offset the margin squeeze from lower prices and intensifying rivalry with Eli Lilly. The longevity and AI initiatives are strategic tailwinds, but they will take years to crystallise into revenue. For the stock to regain its footing, Novo must demonstrate that its pricing power can be stabilised and its profitability in the GLP-1 franchise defended. The foundation for a base is there, but a rapid return to former highs is unlikely. The recovery is intact, but far from secured.